United Cannabis Corporation announced that Jamaica's Ministry of Health has registered its Prana P5 Hemp Bio Nutrient Capsules, Aromatherapy Roll-On and Sublingual Drops, and approved a Jamaican bilateral partner of the company, Caribbean Research & Development Limited, to begin production in Jamaica. Through CRD, the company now has approval in a legal market to research, cultivate, manufacture, and distribute its CBD-based products in Jamaica and reciprocal countries, giving United Cannabis and CRD immediate means to revenue. The company has begun to secure facilities, hire and train staff and establish necessary contacts. The company expects to commence production within 90 days. Additionally, management believes the ability to produce in Jamaica provides United Cannabis with a real competitive advantage beyond the United States; it enables the company to access other markets. Countries that allow the purchase of hemp-based products from Jamaica currently include Canada, Australia and New Zealand, and the company has begun pursuing strategic partners and customers in those markets. The approval includes the hemp-derived CBD-based formulations from the company's full cannabis-centric product lines. United Cannabis' aromatherapy roll-on collection is a holistic, solvent-less botanical transdermal oil made from ratio-specific whole plant cannabis oil, cannabis-derived terpenes, almond oil, wild arnica, lavender flowers, juniper berry, and roman chamomile. Patients have found these products effective in treating arthritis, neuropathy, acute pain, joint aches, muscle tension, muscle spasms, muscle recovery, migraines, and various skin conditions. The Prana Sublingual Collection is another effective delivery mechanism for United Cannabis' proprietary cannabis-centric therapies. Prana Sublingual Drops are available in 5 categories, "raw" and "active" formulations, and accurately deliver 1mg doses for patients. Prana Sublingual drops are an alternative to the oral route and are particularly useful when a rapid onset of micro-dosing is desired, with better patient compliance than oral tablets.